Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27977488 | 0.88 | — | — | |
| SCHEMBL11201877 | 0.74 | CDC42 (0.41) | ALDH1A1KDM4EADRA2CMAPTKMT2A | |
| SCHEMBL11201961 | 0.70 | ADRA2C (0.41) | ALDH1A1KDM4EADRA2CMAPTKMT2A | |
| SCHEMBL11198170 | 0.70 | ALDH1A1 (0.36) | ALDH1A1KDM4EADRA2CMAPTKMT2A | |
| SCHEMBL11197597 | 0.69 | CDC42 (0.40) | ALDH1A1KDM4EADRA2CMAPTGAA | |
| SCHEMBL2560148 | 0.68 | KDM4E (0.34) | ALDH1A1KDM4EADRA2CMAPTGAA | |
| SCHEMBL11201084 | 0.67 | KDM4E (0.39) | ALDH1A1KDM4EADRA2CMAPTGAA | |
| SCHEMBL19044201 | 0.67 | IDO1 (0.36) | ALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL29649258 | 0.67 | CYP17A1 (0.34) | ALDH1A1MAPT | |
| SCHEMBL27334843 | 0.67 | ALDH1A1 (0.39) | ALDH1A1KDM4EADRA2CMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110072864-A | TDO2 INHIBITORS | 基因泰克公司 | 2019-07-30 | — | — | CN | claimed |
| US-20230219890-A1 | BICYCLIC COMPOUNDS AND USE THEREOF | BETTA PHARMACEUTICALS CO LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2023066377-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 索智生物科技（浙江）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-20220306635-A1 | TDO2 Inhibitors | GENENTECH, INC. | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219890-A1 | BICYCLIC COMPOUNDS AND USE THEREOF | CYP11B2, CYP11B1, CYP1B1 | ALDH1A1 445/4885KDM4E 3088/4885ADRA2C 213/4885 |
| US-20220306635-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | ALDH1A1 1849/4885KDM4E 827/4885ADRA2C 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.